William "Andy" Nish, MD, an allergist and immunologist at Northeast Georgia Physicians Group, discusses the factors that influence whether patients with asthma should be prescribed a biologic therapy.
William "Andy" Nish, MD, is a medical director and provider with a specialty in allergy and immunology at Northeast Georgia Physicians Group in Gainesville, Georgia.
Transcript:
What are some of the factors to consider when deciding whether to start a patient with asthma on a biologic?
Nish: Basically, biologics come into play when they're not doing well with other medicines, like maximal medical therapy. These days, maximum medical therapy would be double or combination medical therapy, like inhaled steroids with long-acting beta agonists, or even triple medical therapy, including anti-muscarinic or anticholinergic inhalers like Trelegy [fluticasone furoate, umeclidinium, and vilanterol]. So, we have 3 arrows of asthma treatment, if you will. Back in the day—and I'm dating myself when I say this—when I was training, we had theophen, albuterol, and steroids by mouth. Then, inhaled steroids came out and that was a huge advancement. And then, combination medicines came out when Advair [fluticasone propionate and salmeterol] came out and that was another huge advancement. Then, the biologics came out and gave us another treatment.
Whenever we have options like that, where we can treat people who otherwise weren't doing well, it's hard to serves as a tremendous advancement. Basically, it's based on the severity of their asthma. So, if they're doing well currently, for sure they don't need biologic. [But what] if they're not doing well in terms of severity and recurrent exacerbations? For instance, if they have 1 or more exacerbations and they go into the ER, they go into the acute care, or they're coming into the office acutely and/or they typically need steroids by mouth a couple times a year—that's not well controlled—if they can't sleep at night, if they can't exercise, if they're missing school, if they're missing work, those are all things that say that they're not well controlled.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More